Bayesian estimation of cost-effectiveness ratios from clinical trials

被引:0
|
作者
Heitjan, DF
Moskowitz, AJ
Whang, W
机构
[1] Columbia Univ, Joseph L Mailman Sch Publ Hlth, Div Biostat, New York, NY 10032 USA
[2] Columbia Univ, Int Ctr Hlth Outcomes & Innovat Res, New York, NY 10032 USA
关键词
Bayesian inference; clinical trials; confidence intervals; cost-effectiveness ratios; net health benefit;
D O I
10.1002/(SICI)1099-1050(199905)8:3<191::AID-HEC409>3.0.CO;2-R
中图分类号
F [经济];
学科分类号
02 ;
摘要
Estimation of the incremental cost-effectiveness ratio (ICER) is difficult for several reasons: treatments that decrease both cost and effectiveness and treatments that increase both cost and effectiveness can yield identical values of the ICER; the ICER is a discontinuous function of the mean difference in effectiveness; and the standard estimate of the ICER is a ratio. To address these difficulties, we have developed a Bayesian methodology that involves computing posterior probabilities for the four quadrants and separate interval estimates of ICER for the quadrants of interest. We compute these quantities by simulating draws from the posterior distribution of the cost and effectiveness parameters and tabulating the appropriate posterior probabilities and quantiles. We demonstrate the method by re-analysing three previously published clinical trials. Copyright (C) 1999 John Wiley & Sons, Ltd.
引用
收藏
页码:191 / 201
页数:11
相关论文
共 50 条
  • [21] Cost-effectiveness analyses alongside randomised clinical trials
    Gray, Alastair M.
    CLINICAL TRIALS, 2006, 3 (06) : 538 - 542
  • [22] Does cost-effectiveness play a role in clinical trials?
    Steele, Tace
    Pawaskar, Manjiri
    Balkrishnan, Rajesh
    Fleischer, Alan
    Feldman, Steven R.
    DERMATOLOGIC THERAPY, 2007, 20 (02) : 110 - 119
  • [23] Cost-effectiveness analysis and incremental cost-effectiveness ratios: uses and pitfalls
    Bambha, K
    Kim, WR
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2004, 16 (06) : 519 - 526
  • [24] Cost-effectiveness calculations from trials - Discussion
    vanZwieten, PA
    Ambrosioni, E
    Sever, PS
    MacMahon, S
    Frohlich, ED
    Krakoff, LR
    Zanchetti, A
    Swales, JD
    Hansson, L
    Mancia, G
    Menard, J
    JOURNAL OF HYPERTENSION, 1996, 14 : S52 - S54
  • [25] Estimating country-specific cost-effectiveness from multinational clinical trials
    Willke, RJ
    Glick, HA
    Polsky, D
    Schulman, K
    HEALTH ECONOMICS, 1998, 7 (06) : 481 - 493
  • [26] Bayesian Hierarchical Models for Cost-Effectiveness Analyses that Use Data from Cluster Randomized Trials
    Grieve, Richard
    Nixon, Richard
    Thompson, Simon G.
    MEDICAL DECISION MAKING, 2010, 30 (02) : 163 - 175
  • [27] Aggregating cost data from multicenter clinical trials: An incremental cost-effectiveness elasticity approach
    Tano, BD
    Stanford, RH
    Pathak, DS
    VALUE IN HEALTH, 2004, 7 (03) : 303 - 303
  • [28] Bayesian cost-effectiveness analysis with two measures of effectiveness:: the cost-effectiveness acceptability plane
    Negrín, MA
    Vázquez-Polo, FJ
    HEALTH ECONOMICS, 2006, 15 (04) : 363 - 372
  • [29] COST-EFFECTIVENESS RATIOS - IN A LEAGUE OF THEIR OWN
    BIRCH, S
    GAFNI, A
    HEALTH POLICY, 1994, 28 (02) : 133 - 141
  • [30] Cost-effectiveness Analysis of Microdose Clinical Trials in Drug Development
    Yamane, Naoe
    Igarashi, Ataru
    Kusama, Makiko
    Maeda, Kazuya
    Ikeda, Toshihiko
    Sugiyama, Yuichi
    DRUG METABOLISM AND PHARMACOKINETICS, 2013, 28 (03) : 187 - 195